David A. Braun, MD, PhD

David A. Braun, MD, PhD, is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center

Articles

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

March 27th 2025

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Dr Braun on Future Directions for Research Into Protein Glycosylation in RCC

January 22nd 2025

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.

Dr Braun on Protein Glycosylation as a Potential Biomarker of Response in RCC

January 20th 2025

David A. Braun, MD, PhD, discusses the potential use of protein glycosylation as a biomarker of response in renal cell carcinoma.

Dr Braun on Advancements in Biomarker Development in RCC

October 31st 2024

David A. Braun, MD, PhD, discusses advancements in biomarker development that could help guide treatment decisions in renal cell carcinoma.

Dr Braun on the Role of Biomarkers in Guiding Adjuvant Treatment for RCC

September 11th 2024

David A. Braun, MD, PhD, discusses the role of biomarkers in guiding adjuvant treatment strategies for renal cell carcinoma.

Dr Braun on the Current Kidney Cancer Treatment Paradigm

August 16th 2024

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.

Dr Braun on Selecting Immune Checkpoint Inhibitor–Based Combos in ccRCC

July 11th 2024

David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma

Dr Braun on Biopsy Site Selection in Biomarker Testing in ccRCC

June 21st 2024

David Braun, MD, PhD, discusses findings from the molecular analysis of the HCRN GU16-260-Cohort A study.

Dr Braun on the Evolution of Immunotherapy Combinations in RCC

May 29th 2024

David A. Braun, MD, PhD, discusses considerations with immunotherapy-based regimens in patients with renal cell carcinoma.

KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

April 12th 2024

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

TKI Monotherapy Data in Non–Clear Cell RCC

April 12th 2024

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

Overview of Non–Clear Cell RCC

April 5th 2024

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Clinical Insights on Belzutifan in Advanced RCC

April 5th 2024

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

March 29th 2024

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

March 29th 2024

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

March 22nd 2024

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

March 22nd 2024

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

March 15th 2024

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

March 15th 2024

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

March 8th 2024

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.